mRNA-LNP Vaccine Manufacturing with High Pressure Homogenizer – Smallnm

Lipid Nanoparticles: The Delivery Vehicle Behind mRNA Medicines

The success of mRNA-based COVID-19 vaccines brought lipid nanoparticle (LNP) technology from academic research to global pharmaceutical manufacturing virtually overnight. At the heart of every mRNA-LNP product is a precisely engineered particle ? typically 60-100 nm in diameter ? composed of ionizable cationic lipids, cholesterol, phospholipids, and PEG-lipids that together protect the fragile mRNA payload and enable cellular delivery. High pressure homogenization is one of the key manufacturing approaches for producing these particles at scale, competing alongside microfluidic mixing as the two dominant production technologies.

While microfluidic mixing has received significant attention for R&D-scale LNP production, high pressure homogenization offers distinct advantages for commercial manufacturing: higher throughput, established scale-up methodology, decades of regulatory precedent in injectable emulsion manufacturing, and the ability to process highly concentrated lipid phases that challenge microfluidic devices.

The LNP Composition and Its Impact on Homogenization

A typical mRNA-LNP formulation contains four lipid components dissolved in ethanol, which is then rapidly mixed with an aqueous phase containing the mRNA at low pH (pH 4-5). The key components:

The homogenization step occurs after initial mixing of the ethanolic lipid phase with the acidic aqueous mRNA phase. The resulting coarse dispersion ? typically containing particles in the 200-500 nm range with broad polydispersity ? is passed through the homogenizer at 800-1200 bar to achieve the target 60-100 nm with narrow size distribution (PDI < 0.2).

Process Flow for mRNA-LNP by HPH

1. Lipid preparation: Four lipid components dissolved in ethanol at controlled molar ratios, filtered through 0.22 ?m membrane
2. mRNA preparation: mRNA dissolved in citrate or acetate buffer at pH 4-5, maintained at 2-8?C
3. Initial mixing: Ethanolic lipid phase rapidly combined with aqueous mRNA phase using T-junction or high-shear mixer, forming coarse LNP dispersion
4. High pressure homogenization: 4-8 passes at 800-1200 bar, with inter-pass cooling to maintain product below 25?C
5. Diafiltration / buffer exchange: Tangential flow filtration (TFF) removes ethanol and raises pH to physiological 7.4
6. Sterile filtration: 0.22 ?m filtration into sterile containers
7. Fill-finish: Aseptic filling into vials or pre-filled syringes

The ethanol removal step (step 5) is critical. LNP particles formed in the presence of 25-40% ethanol are metastable ? as ethanol is removed, the particles undergo structural rearrangement. The homogenization parameters (pressure, passes, temperature control) directly influence how well the particles survive this transition without aggregation or mRNA leakage.

Key Quality Attributes and How HPH Controls Them

Protecting mRNA Integrity During Homogenization

mRNA is a fragile molecule ? a single-strand break renders it non-functional. The intense shear and cavitation forces inside a homogenizer valve could theoretically degrade mRNA. In practice, this risk is managed through several mechanisms:

• Encapsulation protection: Once mRNA is encapsulated within the LNP structure during initial mixing, it is physically shielded from direct shear forces. The LNP acts as a protective carrier.
• Low temperature processing: Running the homogenizer with chilled feed (2-10?C) and inter-pass cooling keeps product temperature below 25?C, minimizing chemical degradation rates. Smallnm pharma homogenizers include integrated heat exchangers for precise temperature control.
• pH optimization: mRNA is more stable at pH 4-5 than at neutral pH. The acidic processing environment contributes to maintaining integrity.
• Modified nucleotide chemistry: Most therapeutic mRNAs use modified nucleosides (e.g., N1-methylpseudouridine) that are inherently more stable and resistant to mechanical degradation.

Analytical characterization ? typically by capillary electrophoresis (CE) or IP-RPLC ? confirms mRNA integrity of >80% post-homogenization when these controls are in place. This is comparable to microfluidic mixing results.

Scale-Up from R&D to Commercial Manufacturing

One of the strongest arguments for HPH in mRNA-LNP manufacturing is the predictable, linear scale-up path:

• Preclinical (1-10 g mRNA): Smallnm 5-10 L/h lab homogenizer, 10-100 mL batches
• Phase I/II Clinical (10-100 g mRNA): Smallnm PTH-20 or 40 L/h pilot homogenizer, 1-10 L batches
• Phase III / Commercial (100-1000+ g mRNA): Smallnm 500-1000 L/h industrial homogenizer, 50-500 L batches

The critical process parameter ? energy density (pressure ? number of passes) ? remains constant across scales. A process developed at 1000 bar ? 6 passes on a lab homogenizer will produce the same particle size distribution at 1000 bar ? 6 passes on a production unit. This eliminates the particle size re-optimization that often delays scale-up with other technologies.

FAQ

How does HPH compare to microfluidic mixing for LNP production?

Microfluidics offers excellent control at small scale (<100 mL/min) but faces throughput limitations above production volumes. HPH scales linearly to thousands of liters per hour. The two technologies can produce comparable particle sizes; the choice often depends on available capital, existing facility capabilities, and throughput requirements. Many companies use microfluidics for early development and transition to HPH for commercial manufacturing.

Can a homogenizer used for LNP production be cleaned for multi-product use?

Yes, but with validated cleaning protocols. Lipids are challenging to remove ? they are hydrophobic and can adhere to stainless steel surfaces. A typical cleaning cycle includes: water flush ? 2% alkaline detergent (NaOH-based) at 60-70?C for 30 min ? water rinse ? 1% phosphoric acid rinse ? final WFI (Water for Injection) rinse until conductivity matches WFI blank. Cleaning validation by TOC (Total Organic Carbon) and conductivity is standard for multi-product facilities.

What is the typical batch time for commercial LNP production?

For a 200 L batch using a 500 L/h homogenizer, the homogenization step (6 passes) takes approximately 2.5 hours. When combined with upstream lipid/mRNA preparation and downstream TFF/sterile filtration, total batch time is typically 8-12 hours ? suitable for a single-shift manufacturing operation.

Does HPH affect the lamellarity (number of bilayers) of LNPs?

HPH tends to produce predominantly unilamellar or paucilamellar (1-3 bilayer) particles, which is the desired morphology for efficient mRNA encapsulation and release. Cryo-TEM imaging is the standard method to confirm LNP morphology during process development.

Accelerate Your mRNA-LNP Program

Smallnm supports nucleic acid delivery programs from preclinical formulation through commercial manufacturing. Our application laboratory can run feasibility trials with your lipid and nucleic acid materials, generating particle size, encapsulation efficiency, and mRNA integrity data to support your IND/IMPD submission.

Contact our nucleic acid delivery team to discuss your LNP manufacturing requirements.